Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference91 articles.
1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008
2. Chronic myelogenous leukemia: Biology and therapy;Faderl;Ann Intern Med,1999
3. Staging and prognosis in chronic myelogenous leukemia;Sokal;Semin Hematol,1988
4. Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse;Savage;Br J Haematol,1997
5. Chronic myelogenous leukemia: A concise update;Kantarjian;Blood,1993
Cited by 140 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A common molecular and cellular pathway in developing Alzheimer and cancer;Biochemistry and Biophysics Reports;2024-03
2. Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies;International Journal of Molecular Sciences;2023-09-09
3. A Concise Review on Analytical Methods for Determination of Nilotinib;Current Analytical Chemistry;2023-08
4. Radotinib Decreases Prion Propagation and Prolongs Survival Times in Models of Prion Disease;International Journal of Molecular Sciences;2023-07-31
5. Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation;European Journal of Medicinal Chemistry;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3